RN927C, a site-specific trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models

Molecular Cancer Therapeutics

Volumn 15, Issue 11, 2016, Pages 2698-2708

  Strop, Pavel ^a   Tran, Thomas Toan ^a   Dorywalska, Magdalena ^a   Delaria, Kathy ^a   Dushin, Russell ^a   Wong, Oi Kwan ^a   Ho, Wei Hsien ^a   Zhou, Dahui ^a   Wu, Aidong ^a   Kraynov, Eugenia ^a   Aschenbrenner, Laura ^a   Han, Bora ^a   O'Donnell, Christopher J ^a   Pons, Jaume ^a   Rajpal, Arvind ^a   Shelton, Dave L ^a   Liu, Shu Hui ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RN 927 C; TROP 2 PROTEIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE; MITOSIS INHIBITION; MOUSE; MOUTH MUCOSA; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; SINGLE DRUG DOSE; SKIN; SOLID TUMOR; SYSTEMATIC REVIEW; THERAPEUTIC INDEX; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; DRUG STABILITY; GENE EXPRESSION; GENETICS; LYSOSOME; METABOLISM; MITOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG STABILITY; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOCONJUGATES; LYSOSOMES; MICE; MITOSIS; MOLECULAR TARGETED THERAPY; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995451007     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0431     Document Type: Article

References (42)

1. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Ann Rev Med 2013; 64: 15-29.
2. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs 2014; 6: 34-45.
3. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev 2016; 68: 3-19.
4. Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cellsurface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A 1981; 78: 5147-50.
5. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: Regulation and clinical/therapeutic implications. Genes Cancer 2015; 6: 84-105.
6. Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008; 7: 280-5.
7. Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res 2013; 73: 3155-67.
8. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-5.
9. Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 2010; 46: 944-53.
10. Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol 2012; 12: 22.
11. Kobayashi H, Minami Y, Anami Y, Kondou Y, Iijima T, Kano J, et al. Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. Virchows Arch 2010; 457: 69-76.
12. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12: 3057-63.
13. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009; 62: 152-8.
14. Fong D, SpizzoG, Gostner JM, Gastl G, Moser P,Krammel C, et al. TROP2: A novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21: 186-91.
15. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010; 9: 253.
16. Stoyanova T, Goldstein AS, CaiH,Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev 2012; 26: 2271-85.
17. Wang J, Zhang K, Grabowska D, Li A, Dong Y, Day R, et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res 2011; 9: 1686-95.
18. Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med 2012; 4: 472-85.
19. Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, et al. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget 2014; 5: 9281-94.
20. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM.Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: Preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011; 17: 3157-69.
21. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibodydrug conjugate: Characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem 2015; 26: 919-31.
22. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 2015; 6: 22496-512.
23. Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJJr, Vahdat LT, et al. First-in-Human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 2015; 21: 3870-8.
24. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004; 10: 7063-70.
25. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of themaytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005; 14: 2436-46.
26. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011; 22: 1994-2004.
27. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Sitespecific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26: 925-32.
28. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30: 184-9.
29. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A 2012; 109: 16101-6.
30. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013; 20: 161-7.
31. OkeleyNM, Toki BE, Zhang X, Jeffrey SC, Burke PJ, Alley SC, et al. Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation. Bioconjug Chem 2013; 24: 1650-5.
32. Zimmerman ES,Heibeck TH, Gill A, Li X, Murray CJ,Madlansacay MR, et al. Production of site-specific antibody-drug conjugates using optimized nonnatural amino acids in a cell-free expression system. BioconjugChem2014; 25: 351-61.
33. Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS, et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem 2014; 25: 1331-41.
34. Beerli RR, Hell T, Merkel AS, Grawunder U. Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS One 2015; 10: E0131177.
35. Grunewald J, Klock HE, Cellitti SE, Bursulaya B, McMullan D, Jones DH, et al. Efficient preparation of site-specific antibody-drug conjugates using phosphopantetheinyl transferases. Bioconjug Chem 2015; 26: 2554-62.
36. Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 2015; 33: 733-5.
37. Kung SutherlandMS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122: 1455-63.
38. Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem 2014; 57: 10527-43.
39. Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem 2015; 26: 650-9.
40. Dorywalska M, Dushin R, Moine L, Farias SE, Zhou D, Navaratnam T, et al. Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design. Mol Cancer Ther 2016; 15: 958-70.
41. Goto H, Tomono Y, Ajiro K, Kosako H, Fujita M, Sakurai M, et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 1999; 274: 25543-9.
42. Burris H. Antibody drug conjugates: Promise beyond breast cancer. San Francisco, CA: SWOG; 2014.